Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 18, Number 1—January 2012

Research

High Prevalence of Multidrug-Resistant Tuberculosis, Swaziland, 2009–2010

Elisabeth Sanchez-PadillaComments to Author , Themba Dlamini, Alexandra Ascorra, Sabine Rüsch-Gerdes, Zerihun Demissie Tefera, Philippe Calain, Roberto de la Tour, Frauke Jochims, Elvira Richter, and Maryline Bonnet
Author affiliations: Epicentre, Paris, France (E. Sanchez-Padilla, A. Ascorra, M. Bonnet); National Tuberculosis Control Programme, Mbabane, Swaziland (T. Dlamini); National Reference Center for Mycobacteria, Borstel, Germany (S. Rüsch-Gerdes, E. Richter); Médecins Sans Frontières, Geneva, Switzerland (Z.D. Tefera, P. Calain, R. de la Tour, F. Jochims)

Main Article

Table 3

Patterns of second-line drug resistance in rifampin- and isoniazid-resistant Mycobacterium tuberculosis isolates, Swaziland, 2009–2010*

Resistance pattern No. (%) isolates resistant to isoniazid or rifampin,† n = 60 No. (%) isolates from case-patients with MDR TB, n = 122
No resistance to second-line drugs 54 (90.0) 72 (49.2)
Any resistance 6 (10.0) 62 (50.8)
  Ethionamide 6 (10.0) 58 (47.5)
  Ofloxacin 0 10 (8.2)
  p-aminosalicylic acid 0 0
  Cycloserine 0 0
  Amikacin 0 2 (1.6)
  Capreomycin 0 3 (2.5)
Specific resistance patterns
  Ethionamide 6 (10.0) 50 (41.0)
  Ethionamide + ofloxacin 0 6 (4.9)
  Ethionamide + amikacin + capreomycin 0 1 (0.8)
  Ethionamide + ofloxacin + amikacin + capreomycin 0 1 (0.8)
  Ofloxacin 0 3 (2.5)
  Capreomycin 0 1 (0.8)
XDR 0 1 (0.8)

*MDR, multidrug resistant; TB, tuberculosis; XDR, extensively drug resistant.
†Isolates from MDR TB patients excluded.

Main Article

TOP